Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Cagrilintide and semaglutide together drive record weight loss in global trial Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors Acta Pharmacologica Sinica Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet